| Date |
Acquired company |
Acquiring company |
Amount |
Related |
| 2019-05-01 |
Brammer Bio (USA - MA) |
Thermo Fisher Scientific (USA - MA) |
$1.7 billion |
Technology - Services |
| 2019-04-04 |
Apceth Biopharma (Germany) |
Hitachi Chemical (Japan) |
€75.5 million |
Technologies - Services - Bioproduction |
| 2019-04-01 |
IFM Tre, a subsidiary of IFM Therapeutics (USA - MA) |
Novartis (Switzerland) |
|
CNS diseases - Inflammatory diseases - Fibrotic diseases - Liver diseases |
| 2019-03-20 |
15% equity interest in Vivet Therapeutics (France) |
Pfizer (USA - NY) |
€45 million (US$51 million) |
Rare Diseases - Metabolic Diseases |
| 2019-03-11 |
Asterias Biotherapeutics (USA - CA) |
Biotime (USA - CA) |
undisclosed |
cell therapy |
| 2019-03-08 |
Stellar Biotechnologies (USA - CA) |
Edesa Biotech (Canada) |
|
- Dermatological diseases - Gastrointestinal diseases
|
| 2019-03-04 |
NightstaR Therapeutics (UK) |
Biogen (USA - MA) |
$800 million |
Ophtalmological diseases - Gene therapy |
| 2019-02-25 |
Spark Therapeutics (USA - PA) |
Roche (Switzerland) |
$ 4.3 billion |
Rare diseases - Genetic diseases - Hematological diseases - Ophtalmological diseases |
| 2019-02-25 |
Clementia Pharmaceuticals (Canada) |
Ipsen (France) |
$1.31 billion |
Rare diseases - Bone diseases - Ophtalmological diseases |
| 2019-02-22 |
Celgene (USA - NJ) |
BMS (USA - NY) |
$74 billion |
Cancer - Oncology - Cardiovascular diseases - Immunological diseases - Inflammatory diseases |
| 2019-02-13 |
Citoxlab (France) |
Charles River Laboratories (USA - MA) |
€448 million |
Technology - Services |
| 2019-01-25 |
Apricus Therapeutics (USA - CA) |
Seelos Therapeutics (USA - NY) |
|
CNS diseases - Rheumatic diseases |
| 2019-01-25 |
Capua BioServices (Italy)) |
Olon (Italy)) |
|
CDMO - Technology - Services |
| 2019-01-23 |
MAB Discovery's antibody generation unit (Germany) |
BioNTech (Germany) |
undisclosed |
Technologies - Services |
| 2019-01-22 |
Tesaro (USA - MA) |
GSK (UK) |
$5.1 billion (£4.0 billion) |
Cancer - Oncology |
| 2019-01-07 |
Loxo Oncology (USA - CT) |
Eli Lilly (USA - IN) |
$ 8 billion |
Cancer - Oncology |
| 2019-01-04 |
Oncotelix |
Mabvax |
|
Cancer - Digestive diseases |
| 2018-12-31 |
Tonipharm (France) |
Recordati (Italy) |
|
OTC |
| 2018-12-21 |
Endocyte (USA - IN) |
Novartis (Switzerland) |
$ 2.1 billion |
Cancer - Oncology |
| 2018-12-20 |
Cellforcure (France) |
Novartis (Switzerland) |
|
CDMO - |
